SCHEMBL7244253

SCHEMBL7244253

c1ccc(CCC(Oc2ccccc2)N2CCCCC2)cc1

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 2/20 0.45
CYP1A2 P05177 3/20 0.44
CYP3A4 P08684 3/20 0.44
CYP2D6 P10635 3/20 0.44
CYP2C19 P33261 3/20 0.44
TSHR P16473 1/20 0.44
SLC6A3 Q01959 2/20 0.42
LTA4H P09960 2/20 0.40
SLC6A4 P31645 2/20 0.40
HRH3 Q9Y5N1 2/20 0.40
SLC6A2 P23975 1/20 0.40
KDM4E B2RXH2 1/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
CYP2C9 P11712 2/20 0.40
KCNA5 P22460 2/20 0.40
KCNH2 Q12809 2/20 0.40
KCNE1 P15382 1/20 0.40
ABCB1 P08183 3/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL28363805 0.81 CYP2D6 (0.40) CYP1A2CYP3A4CYP2D6CYP2C19TSHR
SCHEMBL12130576 0.81 SLC6A3 (0.48) CYP1A2CYP3A4CYP2D6CYP2C19SLC6A3
SCHEMBL12130554 0.80 HRH3 (0.43) CYP1A2CYP3A4CYP2D6CYP2C19TSHR
SCHEMBL12130449 0.80 HRH3 (0.43) CYP1A2CYP3A4CYP2D6CYP2C19TSHR
SCHEMBL5163007 0.79 POLB (0.44) CYP1A2CYP3A4CYP2D6CYP2C19TSHR
SCHEMBL12130553 0.78 SLC6A2 (0.42) CYP1A2CYP3A4CYP2D6CYP2C19SLC6A3
SCHEMBL12130607 0.77 MEN1 (0.43) CYP1A2CYP3A4CYP2D6CYP2C19TSHR
SCHEMBL11064002 0.75 SIGMAR1 (0.41) SIGMAR1CYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL3892465 0.74 NAAA (0.41) CYP2D6CYP2C19HRH3MEN1KMT2A
SCHEMBL12130611 0.74 LTA4H (0.47) SLC6A3LTA4HSLC6A4HRH3SLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6534525-B1 Method of using 2- substituted piperidine analogs as selectively active antagonist of N-methyl-D-aspartate (NMDA) receptor subtypes for treating conditions such as stroke, cerebral ischemia, central nervous system trauma, WARNER-LAMBERT & COMPANY 2003-03-18 US disclosed
US-6124317-A ACTIVE DRUG TREATING STROKE, CEREBRAL ISCHEMIA, CENTRAL NERVOUS SYSTEM TRAUMA, HYPOGLYCEMIA, ANXIETY, CONVULSIONS, AMIOGLYCOSIDE ANTIBIOTICS-INDUCED HEARING LOSS, MIGRAINE HEADACHES, CHRONIC PAIN, GLAUCOMA, CMV RETINITIS, PSYCHOSIS WARNER-LAMBERT COMPANY (US) 2000-09-26 US disclosed
WO-1997023215-A1 2-SUBSTITUTED PIPERIDINE ANALOGS AND THEIR USE AS SUBTYPE-SELECTIVE NMDA RECEPTOR ANTAGONISTS WARNER-LAMBERT COMPANY (US) 1997-07-03 WO disclosed